IP Library › Granted Patent US 12,427,161
Granted Patent B2
US 12,427,161 · App. 18/506,169 · Granted Sep 30, 2025

Methods for treating and pharmaceutical compositions

Inventors: Eric Williams Mayoux (Gambais, FR); Delphine Behr-Roussel (Viroflay, FR); Francois Giuliano (Paris, FR)
Assignee: Boehringer Ingelheim International GmbH
A61K31/7048A61K31/5575A61K45/06A61P3/10A61P15/10A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,427,161
App. No.
18/506,169
Granted
Sep 30, 2025
Kind
B2
Abstract

The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a sodium glucose co-transporter 2 (SGLT2) inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a SGLT2 inhibitor is administered to the patient. The invention also relates a pharmaceutical composition comprising a SGLT2 inhibitor and a compounds selected from the group consisting of phosphodiesterase 5 (PDE5) inhibitors or alprostadil.

Claims (3)

1. A method for relieving erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome comprising administering a therapeutically effective amount of empagliflozin to the male patient, and further comprising administering one or more medicaments selected from the group consisting of phosphodiesterase 5 (PDE5) inhibitors and alprostadil in an effective amount to increase erectile responses elicited by cavernous nerve stimulation at increasing stimulation frequencies.

2. The method according to claim 1 , wherein the male patient is over the age of 60 years.

3. The method according to claim 1 , wherein empagliflozin is administered in an amount of 2.5 to 25 mg.

Priority Claims (1)
EP 15166057 · Apr 30, 2015 · regional
Continuity (4)
Continuation 17494543 · Oct 5, 2021
Continuation 16446109 · Jun 19, 2019
Continuation 15568602
Related Publication 20240082284A1 · Mar 14, 2024
References Cited (16)
US 11666590B2 · Broedl · 2023 [cited by examiner]
US 20130252908A1 · Mayoux · 2013 [cited by examiner]
US 20140315832A1 · Broedl · 2014 [cited by examiner]
CA 2557801A1 · 2005 [cited by applicant]
WO 2005092877A1 · 2005 [cited by applicant]
Glossary of medical education terms, Institute of International Medical Education. http://www.iime.org/glossary.htm Accessed in Apr. 20, 2024. (Year: 2024). [cited by examiner]
Takakura et al. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. Life Sciences 147 (2016) 125-131. (Year: 2016). [cited by examiner]
Kohan et al. Interleukin 1 modulation of renal epithelial glucose and amino acid transport. Am. J. Physiol. 254 (Renal Fluid Electrolyte Physiol. 23): F879-F886, 1988. (Year: 1988). [cited by examiner]
Wagman et al. Current Therapies and Emerging Targets for the Treatment of Diabetes. Current Pharmaceutical Design, 2001, 7, 417-450. (Year: 2001). [cited by examiner]
Romeo et al. Sexual Function in Men With Diabetes Type 2: Association With Glycemic Control. Journal of Urology, vol. 163, 788-791, Mar. 2000. (Year: 2000). [cited by examiner]
Basu et al. New Treatment Options for Erectile Dysfunction in Patients with Diabetes Mellitus. Drugs 2004; 64 (23): 2667-2688. (Year: 2004). [cited by examiner]
Ho, Chen-Hsun et al. “The Prevalence and the Risk Factors of Testosterone Deficiency in Newly Diagnosed and Previously Known Type 2 Diabetic Men” (2015) International Society for Sexual Medicine, 12, 389-397. [cited by applicant]
Hussar, Daniel A. et al. “2015 New Drug Update” The Consultant Pharmacist, (2015) vol. 30, No. 4, 192-208. [cited by applicant]
Assaly, Rana et al. “Added Benefit of Empagliflozin: Improvement of Erectile Dysfunction in Diabetic Type 2 Rats” (2015) XP-002758690, AN: PREV201500747898; 2 pgs. [cited by applicant]
Weinberg, Aviva E. et al. “Diabetes Severity, Metabolic Syndrome and the Risk of Erectile Dysfunction” (2013) International Society for Sexual Medicine 10:3, 3102-3109. [cited by applicant]
International Search Report for PCT/EP2016/059525 mailed Apr. 28, 2016. [cited by applicant]